Table 1.
Summary of patients and clinical responses
| Patient | Gender | Age | Histology | HLA-I scores | NCR ligands scores | % of ITNK cytotoxicity against K562 | Route of administration | Date of infusion | Dose level | Doses (× 106/kg) | Toxicity | Responses | Response duration (Months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GD001 | M | 47 | NPC | 2 | 5 | 61.5 | I.V. | 2019/04/19 | 1 | 2.26 | None | Progress | NR |
| 2019/04/23 | 1 | 2.26 | |||||||||||
| 2019/04/29 | 1 | 2.54 | |||||||||||
| GD002 | F | 49 | CRC | 1 | 7 | 77.3 | I.V. | 2019/05/13 | 1 | 2.64 | Slight fever, fatigue | Partial remissions | 16 |
| 2019/05/27 | 2 | 7.04 | |||||||||||
| 2019/06/27 | 2 | 5.28 | |||||||||||
| 2019/07/20 | 3 | 10.57 | |||||||||||
| 2019/08/16 | 3 | 8.61 | |||||||||||
| 2019/09/20 | 1 | 2.36 | |||||||||||
| 2019/10/9 | 2 | 3.46 | |||||||||||
| 2019/12/03 | 2 | 4.38 | |||||||||||
| 2020/01/07 | 3 | 12.12 | |||||||||||
| 2020/04/15 | 3 | 11.53 | |||||||||||
| 2020/06/03 | 3 | 9.56 | |||||||||||
| 2020/07/14 | 3 | 9.48 | |||||||||||
| 2020/08/19 | 3 | 9.48 | |||||||||||
| 2020/09/22 | 2 | 5.53 | |||||||||||
| GD003 | M | 42 | Rhabdomyosarcoma | 3 | 3 | 51.0 | I.A. a | 2019/08/02 | 1 | 4.00 | Slight fever, fatigue, muscle pain | Progress | NR |
| 2019/08/16 | 0 | 0.15 | |||||||||||
| 2019/08/29 | 1 | 1.33 | |||||||||||
| GD004 | M | 29 | Melanoma | 1 | 7 | 71.3 | I.A. | 2019/08/16 | 1 | 1.26 | Slight fever, fatigue | Stable | 1 |
| GD005 | F | 61 | Gastric cancer | 1 | 7 | 75..9 | I.V. | 2019/08/28 | 0 | 0.31 | None | Stable | 1 |
| GD006 | F | 28 | AMC | 1 | 6 | 74.0 | I.A. b | 2019/06/09 | 1 | 1.09 | None | Stable | 3 |
| I.V. | 2019/08/11 | 2 | 4.42 | ||||||||||
| GD007 | M | 63 | NSCLC | NA | NA | 91.1 | I.V. | 2019/10/24 | 1 | 3.32 | Slight fever, fatigue | Stable | 3 |
| GD008 | M | 59 | CRC | NA | NA | 83.1 | I.T. c | 2020/03/04 | 1 | 2.51 | Slight fever, fatigue | Stable | 1.5 |
| I.V. | 2020/03/09 | 1 | 2.51 | ||||||||||
| GD009 | M | 68 | Melanoma | NA | NA | 15.1 | I.V. | 2019/08/27 | 1 | 2.37 | Slight fever | Progress | NR |
| I.V. | 2019/10/01 | 2 | 3.36 |
I.V intravenous, I.A.a Hepatic arterial and ascending aortic injection, I.A.b uterine artery injection, I.T.c intra-tumour injected, Information of the seven patients in the ITNK clinical trial on gender, age, cancer type, HLA-I and NCR ligands expression in tumour biopsy, ITNK cytotoxicity, ITNK infusion dosage, toxicity, clinical outcomes and response duration. NPC nasopharyngeal carcinoma, CRC colorectal cancer, AMC appendices mucinous cystadenocarcinoma, NSCLC non-small cell lung carcinoma, NA not available, NR no response